Anemia, Autoimmune Hemolytic (AHA)

Categories: Blood diseases, Fetal diseases, Genetic diseases, Immune diseases, Metabolic diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Anemia, Autoimmune Hemolytic

MalaCards integrated aliases for Anemia, Autoimmune Hemolytic:

Name: Anemia, Autoimmune Hemolytic 57
Autoimmune Hemolytic Anemia 11 19 58 75 28 53 5 14 71
Idiopathic Autoimmune Hemolytic Anemia 19 71
Anemia, Hemolytic, Autoimmune 43 16
Immuno-Hemolytic Anemia 19 71
Familial Auto-Immune Hemolytic Anemia 19
Acquired Autoimmune Hemolytic Anemia 19
Autoimmune Haemolytic Anaemia 11
Autoimmune Hemolytic Anaemia 11
Anemia Hemolytic Autoimmune 19
Aiha 58
Aha 58



Anemia, Autoimmune Hemolytic: Autosomal recessive 57
Autoimmune Hemolytic Anemia: Multigenic/multifactorial 58


Autoimmune Hemolytic Anemia: 1-9/100000 (Europe, United States) 1-5/10000 (Denmark) 58

Age Of Onset:

Autoimmune Hemolytic Anemia: All ages 58


Orphanet: 58  
Rare haematological diseases

External Ids:

Disease Ontology 11 DOID:718
OMIM® 57 205700
ICD9CM 34 283.0
MeSH 43 D000744
NCIt 49 C34378
SNOMED-CT 68 25121006
MESH via Orphanet 44 D000744
ICD10 via Orphanet 32 D59.0 D59.1
UMLS via Orphanet 72 C0002880
Orphanet 58 ORPHA98375
MedGen 40 C0002880
UMLS 71 C0002880 C0543663 C2931849

Summaries for Anemia, Autoimmune Hemolytic

GARD: 19 Autoimmune hemolytic anemia (AIHA) occurs when your immune system makes antibodies that attack your red blood cells. This causes a drop in the number of red blood cells, leading to hemolytic anemia. Symptoms may include unusual weakness and fatigue with tachycardia and breathing difficulties, jaundice, dark urine and/or splenomegaly. AIHA can be primary (idiopathic) or result from an underlying disease or medication. The condition may develop gradually or occur suddenly.

MalaCards based summary: Anemia, Autoimmune Hemolytic, also known as autoimmune hemolytic anemia, is related to evans' syndrome and splenic marginal zone lymphoma. An important gene associated with Anemia, Autoimmune Hemolytic is TLR8 (Toll Like Receptor 8), and among its related pathways/superpathways are Class I MHC mediated antigen processing and presentation and Innate Immune System. The drugs Tacrolimus and Calcineurin Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and heart, and related phenotypes are muscle weakness and fatigue

Orphanet: 58 A rare, autoimmune disorder in which various types of auto-antibodies are directed against red blood cells causing their survival to be shortened and resulting in hemolytic anemia.

Disease Ontology: 11 An autoimmune disease of blood that is characterized by deficient red blood cells caused by auto-antibodies.

Wikipedia: 75 Autoimmune hemolytic anemia (AIHA) occurs when antibodies directed against the person's own red blood... more...

More information from OMIM: 205700

Related Diseases for Anemia, Autoimmune Hemolytic

Diseases in the Hemolytic Anemia family:

Anemia, Autoimmune Hemolytic Congenital Hemolytic Anemia
Rare Acquired Hemolytic Anemia Hemolytic Anemia Due to Erythrocyte Adenosine Deaminase Overproduction
Hemolytic Anemia Due to an Erythrocyte Nucleotide Metabolism Disorder Hemolytic Anemia Due to a Disorder of Glycolytic Enzymes
Hemolytic Anemia Due to Hexose Monophosphate Shunt and Glutathione Metabolism Anomalies Rare Hemolytic Anemia

Diseases related to Anemia, Autoimmune Hemolytic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1141)
# Related Disease Score Top Affiliating Genes
1 evans' syndrome 32.7 LRBA HP CTLA4 CD8A CD4 CD19
2 splenic marginal zone lymphoma 32.4 CD5 CD19 CCR6
3 autoimmune lymphoproliferative syndrome, type iia 32.4 CD8A CD4
4 common variable immunodeficiency 32.2 LRBA ICOSLG CTLA4 CD40LG CD19
5 autoimmune lymphoproliferative syndrome 32.2 LRBA ICOSLG CTLA4 CD8A CD40LG CD4
6 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 32.0 LRBA ICOSLG CTLA4 CD8A CD4 CCR6
7 leukemia, chronic lymphocytic 32.0 ICOSLG CTLA4 CD8A CD59 CD55 CD5
8 common cold 31.7 ICOSLG CD8A CD40LG CD4 CCR6
9 pure red-cell aplasia 31.7 HP CD8A CD4
10 thrombocytopenia due to platelet alloimmunization 31.7 SOCS1 ICOSLG CD8A CD4 CD19 CCR6
11 lymphoproliferative syndrome 31.6 LRBA CTLA4 CD5 CD40LG CCR6
12 thrombocytopenia 31.6 SOCS1 HP CTLA4 CD40LG CD4 C3
13 hemoglobinuria 31.6 HP G6PD CD59 CD55 C3
14 autoimmune disease 31.6 ICOSLG CTLA4 CD55 CD5 CD40LG CCR6
15 thrombocytopenic purpura, autoimmune 31.5 SOCS1 LRBA ICOSLG CD8A CD4 CCR6
16 agammaglobulinemia 31.4 TLR8 ICOSLG CD40LG CD19
17 aplastic anemia 31.4 CD8A CD59 CD55 CD4 CCR6
18 viral infectious disease 31.3 TLR8 ICOSLG CTLA4 CD40LG CD4 CCR6
19 colitis 31.3 SOCS1 ICOSLG CTLA4 CD4 CCR6
20 lupus erythematosus 31.3 SOCS1 CTLA4 CD40LG CCR6 C3 C1S
21 pernicious anemia 31.3 ICOSLG CD4 CCR6
22 erythema infectiosum 31.3 CD40LG CD4
23 agammaglobulinemia, x-linked 31.2 LRBA ICOSLG CD40LG CD19 CCR6
24 marginal zone b-cell lymphoma 31.2 ICOSLG CD5 CD19 CCR6
25 human cytomegalovirus infection 31.2 CD8A CD4 CCR6
26 hereditary spherocytosis 31.2 HP GYPA G6PD
27 primary biliary cholangitis 31.2 ICOSLG CTLA4 CD8A CD40LG CD4 CCR6
28 glomerulonephritis 31.2 CD59 CD55 CD40LG C3 C1S
29 pancytopenia 31.2 HP CD8A CD55 CD5 CD4 CD19
30 lymphopenia 31.2 CTLA4 CD59 CD55 CCR6
31 hepatitis a 31.1 GYPA G6PD CTLA4 CD4
32 paroxysmal nocturnal hemoglobinuria 31.1 HP G6PD CD59 CD55
33 sjogren syndrome 31.1 ICOSLG CD40LG CCR6
34 hashimoto thyroiditis 31.1 ICOSLG CTLA4 CD8A CD4 CCR6
35 sclerosing cholangitis 31.1 ICOSLG HP CD8A CD4 CCR6
36 pfeiffer syndrome 31.1 CD8A CD40LG CD4 CD19 CCR6
37 diffuse large b-cell lymphoma 31.1 ICOSLG CD5 CD19 CCR6
38 glucosephosphate dehydrogenase deficiency 31.1 RHCE HP GYPA G6PD
39 crohn's disease 31.1 ICOSLG HP CD8A CD4 CCR6
40 cryptococcal meningitis 31.1 CD8A CD4 CCR6
41 immune deficiency disease 31.0 ICOSLG CTLA4 CD8A CD5 CD40LG CD4
42 cholangitis, primary sclerosing 31.0 ICOSLG CTLA4 CD8A CD4 CCR6
43 bilirubin metabolic disorder 31.0 RHCE HP G6PD CD8A CD4
44 hemophagocytic lymphohistiocytosis 31.0 CTLA4 CD8A CD4 CD19 CCR6
45 cryoglobulinemia, familial mixed 31.0 CD5 CD40LG
46 exanthem 31.0 ICOSLG CTLA4 CD8A CD4 CD19 CCR6
47 myelodysplastic syndrome 31.0 SOCS1 ICOSLG GYPA CD8A CD59 CD55
48 waldenstroem's macroglobulinemia 31.0 CD59 CD5 CD40LG CD19
49 sarcoidosis 1 31.0 ICOSLG CD8A CD4 CCR6
50 autoimmune pancreatitis 31.0 ICOSLG CD4 CCR6

Comorbidity relations with Anemia, Autoimmune Hemolytic via Phenotypic Disease Network (PDN):

Acquired Thrombocytopenia Acute Cystitis
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Leukemia, Chronic Lymphocytic

Graphical network of the top 20 diseases related to Anemia, Autoimmune Hemolytic:

Diseases related to Anemia, Autoimmune Hemolytic

Symptoms & Phenotypes for Anemia, Autoimmune Hemolytic

Human phenotypes related to Anemia, Autoimmune Hemolytic:

58 30 (show all 18)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 muscle weakness 58 30 Hallmark (90%) Very frequent (99-80%)
2 fatigue 58 30 Hallmark (90%) Very frequent (99-80%)
3 autoimmunity 58 30 Hallmark (90%) Very frequent (99-80%)
4 hemolytic anemia 58 30 Hallmark (90%) Very frequent (99-80%)
5 dyspnea 58 30 Hallmark (90%) Very frequent (99-80%)
6 headache 58 30 Hallmark (90%) Very frequent (99-80%)
7 abnormal leukocyte morphology 58 30 Hallmark (90%) Very frequent (99-80%)
8 immunodeficiency 58 30 Frequent (33%) Frequent (79-30%)
9 pallor 58 30 Frequent (33%) Frequent (79-30%)
10 lymphoma 58 30 Frequent (33%) Frequent (79-30%)
11 splenomegaly 58 30 Occasional (7.5%) Occasional (29-5%)
12 fever 58 30 Occasional (7.5%) Occasional (29-5%)
13 congestive heart failure 58 30 Occasional (7.5%) Occasional (29-5%)
14 abdominal pain 58 30 Occasional (7.5%) Occasional (29-5%)
15 arrhythmia 58 30 Occasional (7.5%) Occasional (29-5%)
16 abnormal urinary color 58 30 Occasional (7.5%) Occasional (29-5%)
17 abnormality of metabolism/homeostasis 30 HP:0001939
18 autoimmune hemolytic anemia 30 HP:0001890

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
autoimmune hemolytic anemia

coombs positive
abnormal immunoglobulin in heterozygotes

Clinical features from OMIM®:

205700 (Updated 08-Dec-2022)

MGI Mouse Phenotypes related to Anemia, Autoimmune Hemolytic:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.03 C3 CCR6 CD19 CD4 CD40LG CD55
2 renal/urinary system MP:0005367 9.91 C3 CD19 CD40LG CD55 CD59 CD8A
3 immune system MP:0005387 9.86 C3 CCR6 CD19 CD4 CD40LG CD5
4 hematopoietic system MP:0005397 9.58 C3 CCR6 CD19 CD4 CD40LG CD5

Drugs & Therapeutics for Anemia, Autoimmune Hemolytic

Drugs for Anemia, Autoimmune Hemolytic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
2 Calcineurin Inhibitors Phase 4
Rituximab Approved Phase 3 174722-31-7
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
Prednisolone Approved, Vet_approved Phase 3 50-24-8 4894 5755
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5 1875
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 4159 6741
Alemtuzumab Approved, Investigational Phase 2, Phase 3 216503-57-0
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
Mycophenolic acid Approved, Investigational Phase 3 24280-93-1 446541
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7 4897
14 Immunologic Factors Phase 3
15 Antineoplastic Agents, Hormonal Phase 3
16 Neuroprotective Agents Phase 3
17 Hormones Phase 3
18 Hormone Antagonists Phase 3
19 Antiemetics Phase 3
20 glucocorticoids Phase 3
21 Anti-Inflammatory Agents Phase 3
Methylprednisolone Acetate Phase 3 584547
23 Gastrointestinal Agents Phase 3
24 Protective Agents Phase 3
25 Cyclosporins Phase 3
26 Antifungal Agents Phase 3
27 Dermatologic Agents Phase 3
28 Pharmaceutical Solutions Phase 3
29 Antirheumatic Agents Phase 3
30 Anti-Infective Agents Phase 3
31 Antineoplastic Agents, Immunological Phase 3
32 Anti-Bacterial Agents Phase 3
33 Antitubercular Agents Phase 3
34 Antibiotics, Antitubercular Phase 3
35 Agglutinins Phase 3
36 Chrysarobin Phase 3
37 Autoantibodies Phase 2, Phase 3
Levamisole Approved, Investigational, Vet_approved, Withdrawn Phase 2 14769-73-4 26879
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
Aldesleukin Approved Phase 1, Phase 2 110942-02-4
Lactitol Approved, Investigational Phase 1, Phase 2 585-86-4 157355
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
Lenograstim Approved, Investigational Phase 2 135968-09-1
Acyclovir Approved Phase 2 59277-89-3 2022
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751 657237
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
Eculizumab Approved, Investigational Phase 2 219685-50-4
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860

Interventional clinical trials:

(show top 50) (show all 62)
# Name Status NCT ID Phase Drugs
1 Tacrolimus Treatment for Refractory Autoimmune Cytopenia Unknown status NCT03918265 Phase 4 Tacrolimus
2 Anti-CD20 Antibody Rituximab in Addition to Prednisolone in Treatment of Warm Antibody Related Autoimmune Hemolytic Anemia. A Randomised Danish Multicenter Trial. Completed NCT01134432 Phase 3 prednisolone + mabthera;Prednisolone
3 Rituximab in Adult's Warm Auto-Immune Hemolytic Anemia : a Phase III, Double-bind, Randomised Placebo-controlled Trial Completed NCT01181154 Phase 3 rituximab (Mabthera®);Placebo
4 Low Doses of Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias Completed NCT00749112 Phase 2, Phase 3 Alemtuzumab, Rituximab
5 A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion Completed NCT03347396 Phase 3 BIVV009
6 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion Completed NCT03347422 Phase 3 sutimlimab (BIVV009);placebo
7 Cyclosporine as a Second-line Treatment of Primary Autoimmune Hemolytic Anemia Recruiting NCT05057468 Phase 3 Cyclosporine;Rituximab
8 Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study With a Long-term Open-label Extension Recruiting NCT04119050 Phase 2, Phase 3 M281;Placebo
9 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia Recruiting NCT05073458 Phase 3 parsaclisinib;placebo
10 A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD) Recruiting NCT05096403 Phase 3 Pegcetacoplan
11 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Active, not recruiting NCT03764618 Phase 3 Fostamatinib disodium;Placebo
12 Reappraisal of Second-line Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus Active, not recruiting NCT05057481 Phase 3 Mycophenolate Mofetil 500mg;Rituximab
13 An Open-label Study for Sutimlimab in Participants With Cold Agglutinin Disease (CAD) Who Have Completed the CARDINAL Study (BIVV009-03/EFC16215, Part B) or CADENZA Study (BIVV009-04/EFC16216, Part B) in Japan Active, not recruiting NCT05132127 Phase 3 sutimlimab
14 A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Enrolling by invitation NCT04138927 Phase 3 Fostamatinib disodium
15 A Randomized, Double-Blind, Placebo-Controlled Phase II/III Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HMPL-523 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Not yet recruiting NCT05535933 Phase 2, Phase 3 HMPL-523(300mg PO QD);Placebo
16 Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia: ELaboration of Treatment Approach Unknown status NCT03827603 Phase 2 Ibrutinib
17 An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) Unknown status NCT03226678 Phase 2 APL-2
18 Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia. Unknown status NCT01579110 Phase 2 levamisole;Prednisone
19 A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Completed NCT02612558 Phase 2 Fostamatinib 150 mg bid
20 A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia Completed NCT01345708 Phase 2 prednisone, low dose rituximab
21 The CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicenter Trial on the Safety and Efficacy of Bendamustine and Rituximab Combination Therapy Completed NCT02689986 Phase 2 Bendamustine, Rituximab
22 " Anemil Trial ": Phase I/II Clinical Trial Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment Completed NCT02389231 Phase 1, Phase 2 Interleukine-2
23 Sirolimus for Patients With Chronic and/or Refractory Autoimmune Cytopenias: A Pilot Series Completed NCT00392951 Phase 1, Phase 2 sirolimus
24 Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease Completed NCT00010387 Phase 2 cyclophosphamide;filgrastim
25 Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease Completed NCT01696474 Phase 2 Bortezomib
26 Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicentre Study on the Safety and Efficacy of Rituximab in Combination With Fludarabine. Completed NCT00373594 Phase 2 Rituximab;Fludarabine
27 CHOP Plus Rituximab (CHOP-R) in Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) or CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT) Completed NCT00309881 Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
28 Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients With Cold Agglutinin Disease Using Eculizumab Completed NCT01303952 Phase 2 Eculizumab
29 An Open, One-arm, Prospective Study of a Single Dose Anti-CD20 Monoclonal Antibody Combined With Bortezomib for Treatment of Relapsed Refractory Autoimmune Hemolytic Anemia Recruiting NCT04083014 Phase 2 combination of a single dose anti-CD20 antibody and bortezomib
30 A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Intravenous ANX005 in Subjects With Warm Autoimmune Hemolytic Anemia (wAIHA) Recruiting NCT04691570 Phase 2 ANX005
31 A Multicenter, Open-label, Non-randomized, Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia Recruiting NCT04661033 Phase 1, Phase 2 Isatuximab SAR650984
32 Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study Recruiting NCT05089227 Phase 2 treatment "intervention";treatment "standard"
33 A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia Recruiting NCT05002777 Phase 2 rilzabrutinib
34 A Phase II, Multicenter, Open-label Trial to Determine the Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Recruiting NCT04398459 Phase 2 Ibrutinib
35 An Open-label, Multi-center, Phase 2 Basket Study to Assess Efficacy, Safety and Pharmacokinetics of Iptacopan (LNP023) in Participants With Autoimmune Benign Hematological Disorders Recruiting NCT05086744 Phase 2 Iptacopan
36 A Phase 2 Trial of Acalabrutinib for the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia Active, not recruiting NCT04657094 Phase 2 Acalabrutinib
37 A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia Active, not recruiting NCT03538041 Phase 2 Parsaclisib
38 A Phase 1B/2, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Patients With Warm Autoimmune Hemolytic Anemia (WAIHA) Terminated NCT03075878 Phase 1, Phase 2 ALXN1830
39 A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients With Warm Autoimmune Hemolytic Anemia Terminated NCT04253236 Phase 2 RVT-1401 680 mg/weekly;RVT-1401 340 mg/weekly
40 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study of ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia Withdrawn NCT04256148 Phase 2
41 A Phase 2 Randomized, Dose-blind, Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Autoimmune Hemolytic Anemia (AIHA) and Immune Thrombocytopenia (ITP) Withdrawn NCT04039477 Phase 2 KZR-616
42 A Phase 2, Multiple Ascending Dose, Randomized, Double-Blind, Placebo-Controlled Study of ALXN1830 Administered Subcutaneously in Patients With Warm Autoimmune Hemolytic Anemia (WAIHA) Withdrawn NCT04956276 Phase 2 ALXN1830;Placebo
43 A Prospective Open-label Trial to Assess the Efficacy and Safety of Ixazomib and Dexamethasone in Patients With Refractory Autoimmune Cytopenia Withdrawn NCT03965624 Phase 2 Ninlaro
44 Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study. Completed NCT02502903 Phase 1 BIV009
45 High-Dose Cyclophosphamide With CD34+ Selected Autologous Hematopoietic Cell Support for Treatment of Refractory Chronic Autoimmune Thrombocytopenia Completed NCT00001630 Phase 1
46 A Multicenter, Phase 1b, Open Label, Nonrandomized, Single Dose Study Evaluating the Safety, Tolerability and Activity of BIVV020 in Adults With Cold Agglutinin Disease Completed NCT04269551 Phase 1 BIVV020
47 An Open Label, Long Term, Safety and Tolerability Study of Patients With Cold Agglutinin Disease Previously Treated With BIVV020 Active, not recruiting NCT04802057 Phase 1 BIVV020
48 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055 anti-thymocyte globulin;cyclophosphamide;cyclosporine;filgrastim;methylprednisolone;prednisone
49 Autoimmune Cytopenia: Genetics and Pathophysiological Mechanism in Pediatric Evans Syndrome Unknown status NCT03912129
50 Clinical Characteristics and Treatment Outcomes of Patients With Autoimmune Hemolytic Anemia in Assiut University Hospital Completed NCT03269292

Search NIH Clinical Center for Anemia, Autoimmune Hemolytic

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Immunoglobulins, Intravenous

Cochrane evidence based reviews: anemia, hemolytic, autoimmune

Genetic Tests for Anemia, Autoimmune Hemolytic

Genetic tests related to Anemia, Autoimmune Hemolytic:

# Genetic test Affiliating Genes
1 Autoimmune Hemolytic Anemia 28

Anatomical Context for Anemia, Autoimmune Hemolytic

Organs/tissues related to Anemia, Autoimmune Hemolytic:

MalaCards : T Cells, Bone Marrow, Heart, B Cells, Liver, Spleen, Bone

Publications for Anemia, Autoimmune Hemolytic

Articles related to Anemia, Autoimmune Hemolytic:

(show top 50) (show all 4523)
# Title Authors PMID Year
TLR8/TLR7 dysregulation due to a novel TLR8 mutation causes severe autoimmune hemolytic anemia and autoinflammation in identical twins. 62 5
34981838 2022
Familial autoimmune haemolytic anaemia. 62 57
861649 1977
[Familial autoimmune hemolytic animia (AIHA) with negative Coombs test, lymphocytopenia and hypogammaglobulinemia]. 62 57
1209224 1975
Hereditary aspects of autoimmune hemolytic anemia; a retrospective analysis. 62 57
5660845 1968
14315660 1965
Immuno-hemolytic anemia with familial occurence. 62 57
13007407 1952
Immunodeficiency and bone marrow failure with mosaic and germline TLR8 gain of function. 5
33512449 2021
14124686 1964
Low concentration of serum haptoglobin has impact on understanding complex pathophysiology in patients with acquired bone marrow failure syndromes. 53 62
20376581 2010
Severe autoimmune hemolytic anemia associated with IgM warm auto-antibodies in primary Sjögren's syndrome. 53 62
20374393 2010
Serologic findings in autoimmune hemolytic anemia associated with immunoglobulin M warm autoantibodies. 53 62
18980619 2009
Expression levels of CD47, CD35, CD55, and CD59 on red blood cells and signal-regulatory protein-alpha,beta on monocytes from patients with warm autoimmune hemolytic anemia. 53 62
18954403 2009
[Density-specific distribution of erythrocytes in different types of anemia]. 53 62
19253711 2009
Etiology of hemolysis in two patients with hepatitis A infection: glucose-6-phosphate dehydrogenase deficiency or autoimmune hemolytic anemia. 53 62
18320220 2008
The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias. 53 62
17289551 2007
Aortic valve replacement for a patient with glucose-6-phosphate dehydrogenase deficiency and autoimmune hemolytic anemia. 53 62
15985145 2005
Experience with eosin-5'-maleimide as a diagnostic tool for red cell membrane cytoskeleton disorders. 53 62
14641141 2003
Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. 53 62
12728121 2003
Quantitation of red cell-bound IgG, IgA, and IgM in patients with autoimmune hemolytic anemia and blood donors by enzyme-linked immunosorbent assay. 53 62
15373694 2003
Regulation of the immune response by natural IgM: lessons from warm autoimmune hemolytic anemia. 53 62
12871191 2003
[Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria]. 53 62
11930678 2001
[Application of the gel test using and anti-IgA antiglobulin for the immunologic diagnosis of autoimmune hemolytic anemia with a negative direct Coombs test]. 53 62
10472686 1999
Fatal autoimmune hemolytic anemia in a child due to warm-reactive immunoglobulin M antibody. 53 62
9787330 1998
Erythrocyte membrane proteins reactive with IgG (warm-reacting) anti-red blood cell autoantibodies: II. Antibodies coprecipitating band 3 and glycophorin A. 53 62
7517724 1994
Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib. 62
36331249 2023
Hematologic and Oncologic Emergencies. 62
36415070 2023
Splenectomy as an effective treatment for macrothrombocytopenia in Takenouchi-Kosaki syndrome. 62
36459360 2022
An observational analysis of disease burden in patients with cold agglutinin disease: Results from a large US electronic health record database. 62
36427340 2022
Splenectomy outcomes in patients with autoimmune cytopenias and persistent antiphospholipid antibodies. 62
36208143 2022
Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry"). 62
36206383 2022
Activating de novo monoallelic variants causing inborn errors of immunity in two unrelated children born of HIV-seroconcordant couples. 62
36382434 2022
Blinding Anemia: A Case of Bilateral Sequential Nonarteritic Ischemic Optic Neuropathy Secondary to Warm Autoimmune Hemolytic Anemia. 62
34803137 2022
Systemic loxoscelism induced warm autoimmune hemolytic anemia: clinical series and review. 62
35544675 2022
Cold-type autoimmune hemolytic anaemia in a patient with primary bone marrow diffuse large B-cell lymphoma. 62
35975908 2022
Influence of immunohematological markers on severity of in vivo hemolysis in human warm autoimmune haemolytic anemia. 62
35773127 2022
Targeted next-generation sequencing revealed a novel homozygous mutation in the LRBA gene causes severe haemolysis associated with Inborn Errors of Immunity in an Indian family. 62
35413226 2022
Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study. 62
36403132 2022
Autoimmune haemolytic anaemia. 62
36334945 2022
Autoimmune haemolytic anaemia due to immunodeficiency. 62
36414334 2022
Thalidomide-associated autoimmune hemolytic anemia. 62
36349983 2022
Danazol in Refractory Autoimmune Hemolytic Anemia or Immune Thrombocytopenia: A Case Series Report and Literature Review. 62
36355549 2022
Efficacy and steroid-sparing effect of tacrolimus in patients with autoimmune cytopenia. 62
36066607 2022
Autoimmune Hemolytic Anemia in Inflammatory Bowel Disease-Report of a Case and Review of the Literature. 62
36362944 2022
Novel loss-of-function mutations in TNFAIP3 gene in patients with lupus nephritis. 62
36325013 2022
Post-traumatic growth in adult patients with systemic lupus erythematosus: a cross-sectional study in China. 62
36255484 2022
Systemic lupus erythematosus with disseminated aspergillosis misdiagnosed as lupus encephalopathy: a case report and literature review. 62
36388809 2022
Immune Checkpoint Inhibitor-Related Cytopenias: About 68 Cases from the French Pharmacovigilance Database. 62
36291814 2022
Ruptured dermoid cyst of ovary developing into chronic peritonitis; a rare complication diagnosed by contrast CT: A case study. 62
36268424 2022
Diagnosis and Management of Autoimmune Hemolytic Anemias. 62
36294350 2022
Red blood cell alloimmunization and other transfusion-related complications in patients with transfusion-dependent thalassemia: A multi-center study in Thailand. 62
35986658 2022

Variations for Anemia, Autoimmune Hemolytic

ClinVar genetic disease variations for Anemia, Autoimmune Hemolytic:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TLR8-AS1, TLR8 NM_138636.5(TLR8):c.1715G>T (p.Gly572Val) SNV Pathogenic
1339649 GRCh37: X:12938874-12938874
GRCh38: X:12920755-12920755
2 SOCS1 NM_003745.2(SOCS1):c.476_480dup (p.Met161fs) MICROSAT Likely Pathogenic
977214 rs1470306246 GRCh37: 16:11348855-11348856
GRCh38: 16:11254998-11254999
3 SOCS1 NM_003745.2(SOCS1):c.24del (p.Ala9fs) DEL Likely Pathogenic
977213 rs2069587477 GRCh37: 16:11349312-11349312
GRCh38: 16:11255455-11255455
4 TLR8-AS1, TLR8 NM_138636.5(TLR8):c.2498T>C (p.Phe833Ser) SNV Uncertain Significance
1339650 GRCh37: X:12939657-12939657
GRCh38: X:12921538-12921538

Expression for Anemia, Autoimmune Hemolytic

Search GEO for disease gene expression data for Anemia, Autoimmune Hemolytic.

Pathways for Anemia, Autoimmune Hemolytic

Pathways related to Anemia, Autoimmune Hemolytic according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
12.45 CD59 CD55 CD19 C3 C1S
Show member pathways
5 12.15 TLR8 SOCS1 CTLA4 CD8A CD40LG CD19
Show member pathways
Show member pathways
11.96 CTLA4 CD8A CD40LG CD4
8 11.88 CD8A CD40LG CD19 C3
Show member pathways
11.79 CD59 CD55 C3 C1S
Show member pathways
11.74 C1S C3 CD55 CD59
11 11.65 CD8A CD4 CCR6
12 11.64 CTLA4 CD55 CD40LG C3
13 11.59 CD8A CD4 CD19
14 11.5 SOCS1 CD55 CD40LG CD4
15 11.41 ICOSLG CD40LG CD19 C3
16 11.37 CTLA4 SOCS1 TLR8
17 11.16 GYPA CD8A CD59 CD5 CD4 CD19

GO Terms for Anemia, Autoimmune Hemolytic

Cellular components related to Anemia, Autoimmune Hemolytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005887 10.09 CCR6 CD19 CD4 CD40LG CD5 CD8A
2 plasma membrane GO:0005886 10.09 CCR6 CD19 CD4 CD40LG CD5 CD8A
3 external side of plasma membrane GO:0009897 9.6 TLR8 ICOSLG CTLA4 CD8A CD59 CD5

Biological processes related to Anemia, Autoimmune Hemolytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.7 CTLA4 CD8A CD40LG CD4 CCR6 C3
2 regulation of cytokine production GO:0001817 9.65 TLR8 SOCS1 ICOSLG
3 regulation of complement activation GO:0030449 9.62 CD59 CD55
4 regulation of complement-dependent cytotoxicity GO:1903659 9.46 CD59 CD55
5 immune system process GO:0002376 9.36 TLR8 ICOSLG HP CTLA4 CD8A CD55

Sources for Anemia, Autoimmune Hemolytic

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....